Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNFOLDER 21/14 Study: R-CHOP-14 vs R-CHOP-21 in Aggressive B-Cell Lymphoma
NCT00278408Phase 3Completed
- Sponsor
- German High-Grade Non-Hodgkin Lymphoma Study Group
- Start
- Jan 2006
- Primary completion
- Feb 2018
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone in B-cell non-Hodgkin lymphoma (4 arms), sponsored by German High-Grade Non-Hodgkin Lymphoma Study Group. Primary endpoint: Event-free Survival at 3 years. Started Jan 2006; status: completed.
02
Drugs
rituximabcyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00278408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00278408.